Last reviewed · How we verify

NCT04765280

The Frequency of Central Sensitization in Patients With Chronic Musculoskeletal Pain

Status unknown Last updated 19 January 2023
What this trial tests

trial testing Central sensitization inventory in Central Sensitisation in 500 participants. Status unknown.

Timeline
1 January 2021
Primary endpoint
1 March 2023
30 March 2023

Quick facts

Lead sponsorMarmara University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2021
Primary completion1 March 2023
Estimated completion30 March 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Marmara University

Who can join

Adults 18 to 75, any sex, with Central Sensitisation or Chronic Musculoskeletal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Central sensitization is as increased response to normal or sub-threshold stimuli of central nervous system and its close relationship with in many musculoskeletal diseases with chronic pain has been demonstrated in several studies. However, the effect of central sensitization on disability in these patients is not fully known. In this study, it was aimed to investigate the frequency of central sensitization and its effect on patients with chronic musculoskeletal pain who were admitted to physical medicine and rehabilitation outpatient clinics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Central sensitization inventory

Trials testing the same drug.

Other recruiting trials for Central Sensitisation

Currently open trials in the same condition.

Other Marmara University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04765280.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing